Previous 10 | Next 10 |
Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment - Combining computational expertise with cutting-edge single cell technology Compugen showed PVRIG at the sites of T cell priming in the ...
Compugen To Present New Insights into the Tumor Microenvironment Using Single Cell Spatial Transcriptomics at Keystone Symposium PR Newswire HOLON, Israel , March 14, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunothe...
The Ark Innovation ETF was fallen 60% from its high water mark, far more than 10%ish drop of the handful of growth stocks which top the S&P 500 and NASDAQ100. Charts and tables for price and AUM show clearly the the majority of investors in ARKK bought at the top; most ARKK holder...
Compugen press release (NASDAQ:CGEN): FY Revenue of $660M. Throughout 2021, the company shipped a total of more than 340,000 end-user devices, reflecting the rising demand for individual productivity across many sectors, with education continuing to be a major growth area. $110 million Total ...
Compugen to Present at the Oppenheimer 32nd Annual Global Healthcare Conference PR Newswire HOLON, Israel , March 9, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, ...
Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple Myeloma - First time to demonstrate dominant expression of DNAM-1 axis receptors PVRIG and TIGIT, compared to PD-1, on T and NK cells in bone marrow of multiple myeloma patien...
If you’re looking for penny stocks to buy, you’re likely trying to find cheap stocks under $5. They’re well-known for higher risk and known for just as high rewards if you know what you’re doing. Some of the benefits of buying these lower-priced shares includ...
Compugen Ltd. (CGEN) Q4 2021 Results Conference Call February 24, 2022 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO Yvonne Naughton - Head of Investor Relations and Corporate Communications Henry Adewoye - Chief Medical Officer Ari Krashin - Chief Financial and Operat...
Compugen press release (NASDAQ:CGEN): Q4 GAAP EPS of -$0.10 beats by $0.04. As of December 31, 2021, cash, cash related accounts, short-term and long-term bank deposits totaled to approximately $118 million, compared with approximately $124 million as of December 31, 2020. For further detai...
Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors PR Newswire HOLON, Israel , Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...